NCT04695782 (ReRad II) is a Phase 2 clinical trial of Pencil beam proton radiotherapy in Rectal Cancer Recurrent, sponsored by University of Aarhus.

Who is sponsoring NCT04695782?

NCT04695782 is sponsored by University of Aarhus.

What drugs are being tested in NCT04695782?

Interventions in NCT04695782: Pencil beam proton radiotherapy.

What condition does NCT04695782 study?

NCT04695782 studies Rectal Cancer Recurrent.

Is NCT04695782 still recruiting?

NCT04695782 is currently recruiting now. Last updated 5 January 2021.

Last reviewed 2021-01-05 · How we verify

NCT04695782: ReRad II

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy

Recruiting now Phase 2 Last updated 5 January 2021

What this trial tests

Phase 2 trial testing Pencil beam proton radiotherapy in Rectal Cancer Recurrent in 65 participants. Currently enrolling.

Timeline

10 October 2020

Primary endpoint
31 October 2025

31 October 2028

Quick facts

Lead sponsor	University of Aarhus
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	65
Start date	10 October 2020
Primary completion	31 October 2025
Estimated completion	31 October 2028
Sites	1 location across Denmark

Drugs / interventions tested

Pencil beam proton radiotherapy

Conditions studied

Rectal Cancer Recurrent — all drugs for Rectal Cancer Recurrent →

Sponsor

University of Aarhus

Who can join

18 and older, any sex, with Rectal Cancer Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study design: A prospective phase II, non-randomized observational study of dose-escalated pencil beam proton therapy re-irradiation for pelvic recurrences from rectal cancer. Re-irradiation is either a part of neo-adjuvant treatment or as a definitive treatment strategy for un-resectable recurrences.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Inter-fraction motion robustness in a prospective phase II trial on dose-escalated proton reirradiation for locally recurrent rectal cancer.
Truelsen CG, Rønde HS, Kallehauge JF, Poulsen LØ, et al · · 2024 · cited 3× · PMID 39286771 · DOI 10.1016/j.phro.2024.100634
PTCOG Gastrointestinal Subcommittee Lower Gastrointestinal Tract Malignancies Consensus Statement.
Isabelle Choi J, Wojcieszynski A, Amos RA, Giap H, et al · · 2024 · cited 3× · PMID 38757077 · DOI 10.1016/j.ijpt.2024.100019
Acute toxicity and quality of life in dose-escalated proton reirradiation for locally recurrent rectal cancer: The prospective ReRad II trial.
Truelsen CG, Rønde HS, Kallehauge JF, Szpejewska JE, et al · · 2025 · PMID 40677620 · DOI 10.1016/j.ctro.2025.100999
Comparing robust proton versus online adaptive photon radiotherapy for short-course treatment of rectal cancer.
Hundvin JA, Hege Lilleøren U, Valdman A, Sorcini B, et al · · 2024 · PMID 39559486 · DOI 10.1016/j.phro.2024.100663

Verify or expand the search:

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04695782 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 5 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04695782.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing